Psoriatic Arthritis

Plasma-rich platelet injection, an arthritis therapy, is thought to induce regeneration of damaged cartilage. A Netherlands team looked at existing studies and was not convinced that there is credible proof the therapy works. The studies all had a high-to-moderate risk of bias, they found.

A recent study examined the cost of biologic and non-biologic DMARDs under Medicare Part D and stand-alone coverage plans.

Early diagnosis and treatment is the key to preventing long-term joint damage in patients with psoriatic arthritis.

Allergy sufferers may refrain from voicing sniffle complaints once they hear the benefits associated with the warmer weather.

Patients with joint disease often screen positive for depressive symptoms, according to research from Switzerland.

Although psoriatic arthritis (PsA) only targets those diagnosed with psoriasis, a genetic factor has been discovered that only pinpoints the former.

A measuring tool typically used to assess the activity of rheumatoid arthritis (RA) has proven to be valuable for analyzing disease activity in psoriatic arthritis (PsA) as well.

Although moderate alcohol intake is linked to health benefits, a high consumption can have a negative effect on women.

Patients in the SPIRIT-P1 trial with active psoriatic arthritis treated with ixekizumab achieved significant improvement as measured by ACR20 compared to patients who received placebo.

Using golimumab for long-term treatment of patients with psoriatic arthritis increased functional improvement over time, according to a study published in Arthritis Care & Research.

Fingernail changes beyond the current diagnostic criteria should be considered when observing the signs and symptoms of psoriatic arthritis, according to a study from McMaster University.

Even if a psoriatic arthritis patient is in remission for more than 6 months, a completely drug free remission is not advisable, according to a study from Annals of the Rheumatic Diseases.

Women who use acetaminophen or NSAIDs regularly for years appear to be at increased risk for psoriatic arthritis, data from the Nurses Health Study reveal.

While several new treatment options for plaque psoriasis and psoriatic arthritis have launched in recent years, there is still much work to be done in the field to help patients through long stretches of care.

The array of medications and treatments for plaque psoriasis and psoriatic arthritis continues to expand, giving doctors and patients more choices when deciding on a management plan.

The National Institute for Health and Care Excellence in United Kingdom has recommended Janssen's Stelara for the treatment of psoriatic arthritis, adding to its recommendation of the drug already to treat plaque psoriasis.

Researchers in Germany have figured out the process by which interleukin 4 (IL-4) inhibits inflammation, pointing the way toward a possible treatment for psoriasis, psoriatic arthritis, and other autoimmune diseases.

The medical marijuana program in Connecticut will expand to cover several additional conditions, including psoriatic arthritis.

Researchers have reportedly identified several proteins that are highly prevalent in human psoriasis and may play an important role in the development and progression of the disease and its co-morbidities and complications, including psoriatic arthritis.

Methotrexate and tumor necrosis factor inhibitors may be associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis, according to a meta analysis of previous studies.

Researchers in the United Kingdom may have found a gene that could provide clues for the development of better treatment options for psoriatic arthritis (PsA) patients in the future.

Study shows that regular acetaminophen use may be associated with an increased risk of psoriasis and psoriatic arthritis (PsA), and that long-term NSAID use may be associated with an increased risk of PsA.

Study results show patients with psoriatic arthritis, rheumatoid arthritis, and psoriasis are at higher risk for myocardial infarction, stroke, and other adverse cardiovascular events.

The classic Framingham risk factors underestimate the threat of cardiovascular disease in psoriatic arthritis. But effective treatment appears to ameliorate the risk.

Cosentyx (secukinumab) has been approved in Japan for the treatment of psoriasis vulgaris (also known as plaque psoriasis) and psoriatic arthritis.

(ACR2014) Hot news at last year's American College of Rheumatology annual meeting, the newly approved psoriatic arthritis drug apremilast has proven safe and effective in longer-term studies.

Rheumatic conditions may have an increased association with adverse cardiovascular events, according to research published in the Annals of Rheumatic Diseases.

A psoriatic arthritis patient lost access to her biologic therapy and endured acute renal failure, all due to what these authors call unnecessary testing after a case of pneumonia.

The majority of patients with psoriatic arthritis treated with disease-modifying antirheumatic drugs will switch medications, discontinue treatment, or add an additional medicine, usually within a few months of initiating treatment.

On March 21, 2014, the US Food and Drug Administration announced the approval of Celgene Corporation's Otezla (apremilast), an oral tablet indicated to treat active psoriatic arthritis in adults. Otezla has a single contraindication: known hypersensitivity to the active ingredient or any excipients in Otezla tablets.